Saving changes...

Done

Error

Severe Asthma in Children: From Mechanisms to Disease Modification

Severe Asthma in Children: From Mechanisms to Disease Modification

Severe Asthma in Children: From Mechanisms to Disease Modification

Leonard B. Bacharier (MD FAAAAI), Dr. Theresa W. Guilbert (MD MS), and Dr. Daniel J. Jackson (MD)
Leonard B. Bacharier (MD FAAAAI), Dr. Theresa W. Guilbert (MD MS), and Dr. Daniel J. Jackson (MD)
on behalf of American Academy of Allergy Asthma & Immunology

$15.00 $ 15.00 $ 15.00

$15.00 $ 15.00 $ 15.00

$ 15.00 $ 15.00 $ 15.00
$ 15.00 $ 15.00 $ 15.00
Normal Price: $15.00 $15.00

Review:

Launch date: 29 Jun 2018
Expiry Date:

Last updated: 22 Aug 2018

Reference: 190497

This course is no longer available

Exam is embedded in the course
No preview available
No Exam Available

Latest User Comments

I would like to...

Course Availability

This course is only available to trainees days after purchase. It would need to be repurchased by the trainee if not completed in the allotted time period. This course is no longer available. You will need to repurchase if you wish to take the course again.

Description

Frequent exacerbations are an important feature and associated with significant morbidity, health care utilization and costs.Furthermore, recurrent severe exacerbations may lead to progressive loss of lung function and increased asthma severity over time.Recent studies have helped elucidate mechanisms underlying severe asthma in children. With the emergence of biologic therapies, there has been interest in their role in the prevention of asthma exacerbations and potential utility for disease modification.

Objectives

Describe the frequency and common features of severe asthma in children
Upon completion of this activity, participants will be able to describe the frequency and common features of severe asthma in children.
Identify common underlying mechanisms of severe asthma in children
Upon completion of this activity, participants will be able to identify common underlying mechanisms of severe asthma in children.
Discuss the efficacy of omalizumab and the potential for disease modification in children
Upon completion of this activity, participants will be able to discuss the efficacy of omalizumab and the potential for disease modification in children.
Leonard B. Bacharier (MD FAAAAI), Dr. Theresa W. Guilbert (MD MS), and Dr. Daniel J. Jackson (MD)

Author Information Play Video Bio

Leonard B. Bacharier (MD FAAAAI), Dr. Theresa W. Guilbert (MD MS), and Dr. Daniel J. Jackson (MD)
on behalf of American Academy of Allergy Asthma & Immunology

Leonard B. Bacharier, MD FAAAAI, Washington University School of Medicine and St. Louis Children, Saint Louis, MO

Dr. Theresa W. Guilbert, MD MS, Cincinnati Children's Hospital & Medical Center, Cincinnati, OH

Dr. Daniel J. Jackson, MD, Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI

Current Accreditations

This course has been certified by or provided by the following Certified Organization/s:

  • Accreditation Council for Continuing Medical Education (ACCME)
  • 1.25 Credits
  • California Board of Registered Nursing (CBRN)
  • 1.25 Hours

Faculty and Disclosures

Leonard B. Bacharier, MD FAAAAI

Leonard B. Bacharier, MD FAAAAI

Potential Conflict

Washington University (Professor of
Pediatrics)
Competing Relationships: Honoraria for
lectures – AstraZeneca China, Teva,
Boehringer
Ingelheim; Consultant – DBV Technologies,
Vectura; Advisory Board – Sanofi,
Boehringer
Ingelheim; Investigator – AsthmaNet,
Severe Asthma Research Program, Inner
City Asthma
Consortium, ORBEX trial
Organizational Interests: AAAAI: Fellow,
Associate Editor of JACI, Editorial Board of
JACI: In practice; AAAAI: AMPC Member
Theresa W. Guilbert, MD, MS

Theresa W. Guilbert, MD, MS

No Conflict
Daniel J. Jackson, MD

Daniel J. Jackson, MD

University of Wisconsin School of Medicine
and Public Health (Assistant Professor of
Pediatric
Allergy & Immunology)
Competing Relationships: Grant – NIH –
NIAID, NIH - NHLB

Additional Contributors

Conflicts Declared

Conflicts of Interest declaration by Author:

null

User Reviews (0)

Go Back

Loading...


Saving changes...

Done

Error